On December 27, 2019, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma as detected by an FDA-approved test whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. The FDA also approved the BRACAnalysis CDx test as a companion diagnostic for the selection of patients with pancreatic cancer for treatment with olaparib based upon the identification of deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2 genes.
Efficacy was investigated in POLO, a double-blind, placebo-controlled, multicenter trial that randomly assigned 154 patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma 3:2 to either 300 mg of olaparib orally twice daily or placebo until disease progression or unacceptable toxicity.
The main efficacy outcome measure was progression-free survival (PFS) by blinded independent central review using RECIST version 1.1. Additional efficacy outcome measures were overall survival (OS) and overall response rate (ORR).
Median PFS was 7.4 months (95% confidence interval [CI] = 4.1–11.0) for patients who received olaparib compared with 3.8 months (95% CI = 3.5–4.9) for patients who received placebo (hazard ratio [HR] = 0.53, 95% CI = 0.35–0.81, P = .0035). Median OS for olaparib and placebo was 18.9 months (95% CI = 14.9–26.2) and 18.1 months (95% CI = 12.6–26.1), respectively (HR = 0.91, 95% CI = 0.56–1.46, P = .683); ORR among patients who had measurable disease at baseline was 23% and 12%, respectively.
In general, the adverse reaction profile of olaparib observed in POLO was consistent with the known safety profile of olaparib. The most common adverse reactions to olaparib (≥ 10%) in clinical trials include nausea, fatigue, vomiting, abdominal pain, anemia, diarrhea, dizziness, neutropenia, leukopenia, nasopharyngitis/upper respiratory tract infection/influenza, respiratory tract infection, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, stomatitis, dyspnea, and thrombocytopenia.
The recommended olaparib dose is 300 mg taken orally twice daily with or without food.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.